Parkinson Disease
Conditions
Brief summary
The objectives of this study are to investigate issues or questions about MIRAPEX Tablets as shown below through the Post Marketing Surveillance (PMS) study upon approval. * Unexpected adverse events (especially, serious adverse events (SAEs)) * To find out the status of incidence of adverse events under actual practice * Factors on the safety profile * Factors on the efficacy profile
Interventions
DRUGPramipexole
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Among the patients with idiopathic Parkinson's disease, from those receiving MIRAPEX Tablets first after a contract of the study to the requested number of cases will be consecutively enrolled without skipping
Exclusion criteria
* Following patients are contraindicated. 1. Patients who are hypersensitive to MIRAPEX or its ingredients 2. Refer to the insert paper for other contraindication. * Following patients should be carefully administered. 1. Patient with renal impairment 2. Refer to the insert paper for other precaution.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of Unified Parkinson's disease Rating Scale (UPDRS) | up to 4 weeks | Tremor at rest, Rigidity, Body bradykinesia and hypokinesia |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients with adverse events | up to 4 weeks |
| Global Assessment of efficacy by investigator on 3-point scale | after 4 weeks |
Outcome results
None listed